We're pleased to present our activities report for the quarter ended 31 December 2024 (Q2 FY2025), together with our Appendix 4C Quarterly Cash Flow Report.

View the full $NTI #ASX Announcement here:#NTI164 #ClinicalResearch #Neurotech #NTI #ASX #PaediatricNeurology #biotech #ASX
#NTI #ASX #NTI164 #ClinicalResearch #Neurotech #NTI #ASX